Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer

Share :
Published: 31 Jan 2014
Views: 4486
Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA

Dr Tomasz M. Beer from Oregon Health & Science University, Portland, USA, speaks to ecancer at the ASCO GU congress 2014.  He discusses the results from the phase III PREVAIL trial showing increased survival and delayed progression of mCRPC in men. Data were presented in full for the first time at the GU Cancer symposium.

Dr Beer states that the androgen-receptor blocker enzalutamide is likely to become an important new treatment option if approved.

For more information on this study please click here.